Read by QxMD icon Read


Amparo E Macias, Ramon Ortiz, Eduardo Santiesteban, Xitlally Popa, Anet Zayas, Zaima Mazorra, Ivis Mendoza, Elena Garcia, Roberto Gomez, Tania Crombet
No abstract text is available yet for this article.
October 2016: Journal of Thoracic Oncology
Carlos O Cobian, Soraida C Acosta Brooks, Francisco M Feria, Lázaro I Romero
No abstract text is available yet for this article.
October 2016: Journal of Thoracic Oncology
Giannis Mountzios, Helena Linardou, Paris Kosmidis
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death worldwide. In recent years, through a better understanding of the interactions between the immune system and tumor cells (TC), immunotherapy has emerged as a promising therapeutic strategy. Chemotherapy has long been reported to interfere with the immune response to the tumor and conversely, anti-tumor immunity may add to those effects. Anti-tumor vaccines, such as MAGE-A3, Tecetomide, TG4010, CIMAvax, tumor cell vaccines and dendritic cell (DC) vaccines emerged as potent inducers of the immune response against the tumor...
July 2016: Annals of Translational Medicine
Pedro C Rodriguez, Xitllaly Popa, Odeth Martínez, Silvia Mendoza, Eduardo Santiesteban, Tatiana Crespo, Rosa M Amador, Ricardo Fleytas, Soraida C Acosta, Yanine Otero, Gala N Romero, Ana de la Torre, Mireysi Cala, Lina Arzuaga, Loisel Vello, Delmairis Reyes, Niurka Futiel, Teresa Sabates, Mauricio Catala, Yoanna I Flores, Beatriz Garcia, Carmen Viada, Patricia Lorenzo-Luaces, Maria A Marrero, Liuba Alonso, Jenelin Parra, Nadia Aguilera, Yaisel Pomares, Patricia Sierra, Gryssell Rodríguez, Zaima Mazorra, Agustin Lage, Tania Crombet, Elia Neninger
PURPOSE: EGFR is a well-validated target for patients with non-small cell lung cancer (NSCLC). CIMAvax-EGF is a therapeutic cancer vaccine composed of human recombinant EGF conjugated to a carrier protein and Montanide ISA51 as adjuvant. The vaccine is intended to induce antibodies against self EGFs that block EGF-EGFR interaction. EXPERIMENTAL DESIGN: To evaluate overall survival, safety, immunogenicity, and EGF concentration in serum after CIMAvax-EGF, a randomized phase III trial was done in patients with advanced NSCLC...
August 1, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Tania Crombet Ramos, Pedro Camilo Rodríguez, Elia Neninger Vinageras, Beatriz Garcia Verdecia, Agustin Lage Davila
Epidermal growth factor receptor (EGFR) is overexpressed in many epithelial tumors and its role in the development of non-small-cell lung cancer (NSCLC) is widely documented. CIMAvax-EGF is a therapeutic cancer vaccine composed by recombinant EGF conjugated to a carrier protein and emulsified in Montanide ISA51. Vaccination induces antibodies against self-EGF that block EGF-EGFR interaction and inhibit EGFR phosphorylation. Five clinical trials were conducted to optimize vaccine formulation and schedule. Then, two randomized studies were completed in advanced NSCLC, where CIMAvax-EGF was administered after chemotherapy, as 'switch maintenance'...
2015: Expert Review of Vaccines
Duarte Domingues, Alice Turner, Maria Dília Silva, Dânia Sofia Marques, Juan Carlos Mellidez, Luciano Wannesson, Giannis Mountzios, Ramon Andrade de Mello
Non-small-cell lung cancer (NSCLC) is a highly prevalent and aggressive disease. In the metastatic setting, major advances include the incorporation of immunotherapy and targeted therapies into the clinician's therapeutic armamentarium. Standard chemotherapeutic regimens have long been reported to interfere with the immune response to the tumor; conversely, antitumor immunity may add to the effects of those therapies. The aim of immunotherapy is to specifically enhance the immune response directed to the tumor...
2014: Immunotherapy
Rossana Ruiz, Brian Hunis, Luis E Raez
Non-small-cell lung cancer usually carries a dismal prognosis. Novel treatment approaches are clearly warranted. Immunotherapy has emerged as a promising area of research developing agents that manipulate the immune system to induce antitumor responses while avoiding major toxicity. New vaccines and checkpoint inhibitors are currently undergoing investigation in phase II and phase III clinical trials. In advanced non-small-cell lung cancer (NSCLC), belagenpumatucel-L, an allogeneic cell vaccine directed against transforming growth factor β in the tumor microenvironment, knocks down the immune suppression caused by the tumor and has demonstrated a dose- and time-dependent efficacy in some subgroups of patients...
September 2014: Current Oncology Reports
Zaima Mazorra Herrera, Tania Crombet Ramos
Cancer vaccines contain tumor antigens in a pro-inflammatory context with the purpose to generate potent antitumor immune responses. However, tumor cells develop different immunosuppressive mechanisms that limit the effectiveness of an anticancer immune response. Therefore, therapeutic vaccine treatment alone is usually not sufficient to generate tumor regression or survival improvement, especially in the advanced disease scenario in which most clinical studies have been conducted. Combining cancer vaccines with different anticancer therapies such as chemotherapy, radiotherapy and other immunotherapeutic agents has had different levels of success...
July 2014: Cancer Immunology, Immunotherapy: CII
Aymara Fernández Lorente, Soraida Acosta Brooks, Elia Neninger Vinageras, María del Carmen Barroso Alvarez, Barbara Wilkinson Brito, Mayelin Troche Concepción, Liana B Martínez Pérez, Carmen E Viada González, Tatiana Crespo Diaz, Angel Raymundo Casacó Parada
BACKGROUND: The epidermal growth factor receptor (EGFR) signaling system is frequently unbalanced in human malignancies due to increased ligand production, receptor overexpression, receptor mutations, and/or cross-talk with other receptor systems. For this reason, the EGFR is an attractive target for anticancer therapy. The epidermal growth factor also plays an important role in regulating multiple facets of cutaneous wound healing, including inflammation, wound contraction, proliferation, migration, and angiogenesis...
2013: World Journal of Surgical Oncology
Jian Y Cheng, Ratnavelu Kananathan
This case report documents the use of the CIMAvax Epidermal Growth Factor vaccine regimen in a 54 y old female with stage IIIb non-small cell lung carcinoma. Even after 48 mo since diagnosis her ECOG performance remains at zero. Further, this report documents a reaction to the vaccine of grade 3 severity not previously documented.
December 1, 2012: Human Vaccines & Immunotherapeutics
A Mancebo, A Casacó, B González, N Ledón, J Sorlozabal, A León, D Gómez, Y González, A M Bada, C González, M E Arteaga, H Ramírez, D Fuentes
CIMAvax-EGF consists of a human recombinant epidermal growth factor (EGF), coupled to P64k, a recombinant carrier protein from N. meningitis, and Montanide ISA 51 as adjuvant. The vaccine immunization induces a specific antibody production, inhibiting the EGF/EGF-R interaction through EGF deprivation. The objective of this study was to assess the CIMAvax-EGF toxicity in Sprague Dawley rats after intramuscular administration of repeated doses (6 months) and at the same time to determine if rat is a relevant species for studying CIMAvax-EGF vaccine...
May 9, 2012: Vaccine
Pedro C Rodriguez, Elia Neninger, Beatriz García, Xitlally Popa, Carmen Viada, Patricia Luaces, Gisela González, Agustin Lage, Enrique Montero, Tania Crombet
The prognosis of patients with advanced non small cell lung (NSCLC) cancer remains dismal. Epidermal Growth Factor Receptor is over-expressed in many epithelial derived tumors and its role in the development and progression of NSCLC is widely documented. CimaVax-EGF is a therapeutic cancer vaccine composed by human recombinant Epidermal Growth Factor (EGF) conjugated to a carrier protein, P64K from Neisseria Meningitides. The vaccine is intended to induce antibodies against self EGF that would block EGF-EGFR interaction...
2011: Journal of Immune Based Therapies and Vaccines
Cesar A Perez, Edgardo S Santos, Luis E Raez
Lung cancer remains the number one cause of cancer-related death worldwide. Active cancer immunotherapy is a growing field that is included as one of the most important modalities used to modify the host immune system for the treatment of malignancies. With the recent approval of sipuleucel-T for the treatment of prostate cancer, immunotherapy has become a reality in the treatment of solid tumors. Different therapeutic cancer vaccines, aimed to create specific anti-tumor immunity, are currently under clinical development in non-small-cell lung cancer (NSCLC)...
October 2011: Expert Review of Anticancer Therapy
Pedro C Rodríguez, Gryssell Rodríguez, Gisela González, Agustín Lage
INTRODUCTION: CIMAvax EGF is a therapeutic anticancer vaccine developed entirely in Cuba and licensed in Cuba for use in adult patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). The vaccine is based on active immunotherapy by which an individual's immune response is manipulated to release its own effector antibodies (Abs) against the epidermal growth factor (EGF). OBJECTIVE: Review pre-clinical and clinical research conducted during development of CIMAvax EGF, primarily studies published by Cuban investigators in international peer-reviewed scientific journals...
2010: MEDICC Review
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"